Mesoblast Ltd Sp ADR (MBLTY) 22.0100 $MBLTY
Diabetic Nephropathy - Pipeline Review, H1 2014: 37 Companies and 58 Drugs Profiled
M2 - 31 mins ago
Research and Markets (http://www.researchandmarkets.com/research/x6n63h/diabetic) has announced the addition of the "Diabetic Nephropathy - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Nephropathy and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diabetic Nephropathy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diabetic Nephropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved: - AbbVie Inc. - Ampio Pharmaceuticals, Inc. - Angelini Group - Astellas Pharma Inc. - Bayer AG - CCRP Therapeutics GmbH - ChemoCentryx, Inc. - Chong Kun Dang Pharmaceutical Corp. - Concert Pharmaceuticals, Inc. - Cyano Biotech GmbH - Daiichi Sankyo Company, Limited - Dongwha Pharm Co., Ltd. - Eli Lilly and Company - Emergent BioSolutions Inc. - Fibrotech Therapeutics Pty. Ltd. - GNI Group Ltd. - Galectin Therapeutics - GenKyoTex S.A. - Gentium S.p.A. - Glucox Biotech AB - IMMD Inc. - Intercept Pharmaceuticals, Inc. - Inventiva SAS - Johnson & Johnson - Mesoblast Limited - Mitsubishi Pharmaceutical Corporation - Mitsubishi Tanabe Pharma Corporation - NephroGenex, Inc. - Noxxon Pharma AG Drug Profiles: - canagliflozin - atrasentan hydrochloride - baricitinib - NOX-E-36 - IMD-1041 - CS-3150 - DW-1029M - GKT-137831 - PF-00489791 - CCX-140 - LY-2382770 - bindarit - Colchicine - probucol - PF-04634817 - Pyridoxamine Dihydrochloride - GLY-230 - corticotropin - CTP-499 - MT-3995 - finerenone - cilostazol - PHN-033 - CKD-322 - Allogeneic Mesenchymal Precursor Cells For Diabetic Nephropathy - LY-3016859 - FT-011 - ASP-8232 - pirfenidone - THR-123 For more information visit http://www.researchandmarkets.com/research/x6n63h/diabetic
Angina (Angina Pectoris) - Pipeline Review, H1 2014: 11 Company and 15 Drug Profiles
M2 - Wed May 07, 9:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/shfvfz/angina_angina) has announced the addition of the "Angina (Angina Pectoris) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Angina (Angina Pectoris), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Angina (Angina Pectoris) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - Bayer AG - Cardiolynx AG - Cardium Therapeutics, Inc. - Cheiljedang Corporation - Diakron Pharmaceuticals, Inc. - Juventas Therapeutics, Inc. - Kuhnil Pharmaceutical Co., Ltd. - Lacer, S.A. - Mesoblast Limited - Milestone Pharmaceuticals, Inc. - ViroMed Co., Ltd. Drug Profiles: - alferminogene tadenovec - VM-202 - VM-202 - CJ-30059 - ACP-01 - Organic Nitrate For Angina Pectoris - CLC-1201 - DP-3005 - JVS-100 - CEP-41750 - LA-8045 - MSP-2017 - BAY-606583 - KI-1007 - R-06 For more information visit http://www.researchandmarkets.com/research/sh...ina_angina
Chronic Heart Failure - Pipeline Review, H1 2014: 22 Company and 30 Drugs Profiled
M2 - Wed May 07, 9:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dlbpvz/chronic_heart) has announced the addition of the "Chronic Heart Failure - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Heart Failure and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - Bayer AG - Cardioxyl Pharmaceuticals, Inc. - Celladon Corporation - Cyano Biotech GmbH - Fibrotech Therapeutics Pty. Ltd. - Hospira, Inc. - Laboratoires Pierre Fabre SA - Les Laboratoires Servier SAS - Mesoblast Limited - MetrioPharm AG - NormOxys, Inc. - Novartis AG - Otsuka Holdings Co., Ltd. - Palatin Technologies, Inc. - Pfizer Inc. - PhaseBio Pharmaceuticals, Inc. - Provasculon, Inc. - Sanofi - Scynexis, Inc. - Zensun (Shanghai) Sci & Tech Co., Ltd. - miRagen Therapeutics, Inc. - t2cure GmbH Drug Profiles: - Neucardin - rivaroxaban - (AHU-377 valsartan) - CEP-41750 - aliskiren fumarate - sildenafil citrate - PL-3994 - CXL-1020 - tolvaptan - somatropin - Neucardin - finerenone - ivabradine - F-373280 - BMCs - cenderitide - OXY-111A - MGN-9103 - MP-2000 - BR-5489 - Small Molecule Allosteric Modulators Of SERCA2a - FT-011 - PB-1046 - SAR-296968 - PRV-0023 - Cyclophilin Inhibitory Compounds - etomoxir - PRV-0023 - Microginins ACE Inhibitors? Program - Vestiras For more information visit http://www.researchandmarkets.com/research/dl...onic_heart
Stem Cell Therapy Market by Treatment Mode (Autologous & Allogeneic), Therapeutic Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) - Global Forecasts to 2020
M2 - Tue May 06, 10:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wwnrd5/stem_cell_therapy) has announced the addition of the "Stem Cell Therapy Market by Treatment Mode (Autologous & Allogeneic), Therapeutic Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) - Regulatory Landscape, Pipeline Analysis & Global Forecasts to 2020" report to their offering. The global stem cell therapy market on the basis of the mode of treatment is segmented into allogeneic and autologous stem cell therapy. The allogeneic stem cell therapy is expected to command the largest share of the market in 2015, and is also expected to grow at a higher CAGR than autologous therapies from 2015 to 2020. Based on the therapeutic applications, the global market is segmented into eye diseases, metabolic diseases, GIT diseases, musculoskeletal disorders, immune system diseases, CNS diseases, CVS diseases, wounds and injuries, and others. A number of factors such as increasing funding from government and private organizations, growing industry focus on stem cell research, and increasing global awareness about stem cell therapies through various organizations are driving the growth of the global market. Furthermore, increasing funding for new stem cell lines, development of advanced genomic methods for stem cell analysis, and rising approvals of clinical trials for stem cells therapy are other factors that are propelling the growth of the market. Key Topics Covered: 1 INTRODUCTION 2 EXECUTIVE SUMMARY 3 MARKET DYNAMICS 4 PIPELINE ANALYSIS 5 INVESTOR NETWORK 6 GLOBAL STEM CELL THERAPY MARKET, BY MODE OF THERAPY 7 GLOBAL STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATIONS 8 REGULATORY LANDSCAPE 9 GLOBAL STEM CELL THERAPY MARKET, BY GEOGRAPHY 10 COMPETITIVE LANDSCAPE 11 COMPANY PROFILES Companies Mentioned: - Aastrom Biosciences Inc. - Advanced Cell Technologies, Inc. - Athersys Inc. - Celgene Corporation - Cellular Dynamics International - Cytori Therapeutics, Inc. - Fibrocell Science, Inc. - Gamida Cell Ltd. - Mesoblast Ltd. - Pluristem Therapeutics Inc. - StemCells Inc. For more information visit http://www.researchandmarkets.com/research/ww...ll_therapy
Mesoblast Provides Update on Clinical Programs of Prochymal for Crohn's Disease and Acute Graft Versus Host Disease
GlobeNewswire - Mon Apr 28, 8:54PM CDT
Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today provided an update on its clinical programs using the product Prochymal(R), which was acquired as part of the entire culture-expanded mesenchymal stem cell (MSC) business of Osiris Therapeutics (NASDAQ:OSIR) by the Mesoblast Group.
Global Bone Marrow Transplantation Therapeutic Pipeline Review
M2 - Mon Apr 28, 11:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lrc2d3/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Marrow Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation and special features on late-stage and discontinued projects. Companies Involved in Therapeutics Development - Mesoblast Limited - Cleveland BioLabs, Inc. - Compugen Ltd. - Pluristem Therapeutics Inc. - Spectrum Pharmaceuticals, Inc. - TikoMed AB - Taiga Biotechnologies, Inc. Drug Profiles - Allogeneic MPC For Bone Marrow Transplantation - melphalan - TM-400 - PLX-BMP - CBLB-612 - CBLB-612 - CGEN-15001 - Small Molecule to Inhibit Perforin for Bone Marrow Transplantation - Protein for Bone Marrow Transplantation Companies Mentioned: - Mesoblast Limited - Cleveland BioLabs, Inc. - Compugen Ltd. - Pluristem Therapeutics Inc. - Spectrum Pharmaceuticals, Inc. - TikoMed AB - Taiga Biotechnologies, Inc. For more information visit http://www.researchandmarkets.com/research/lr...one_marrow
Osiris receives USD15m cash payment for Prochymal business acquisition
M2 - Thu Apr 10, 7:06AM CDT
US-based stem cell company Osiris Therapeutics (NasdaqGM :OSIR) reported on Wednesday the receipt of the next payment of USD15m in cash from Mesoblast under the Purchase Agreement relating to the Prochymal business.
Osiris Announces Receipt of $15 Million Cash Payment for Prochymal
Business Wire - Wed Apr 09, 7:01AM CDT
Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading stem cell company focused on developing and marketing products to treat conditions in wound care, orthopedic and sports medicine markets, announced that it has received the next $15 million cash payment from Mesoblast in accordance with the Purchase Agreement relating to the Prochymal business.
Key Pharmaceutical Executive Joins Mesoblast
GlobeNewswire - Mon Mar 10, 6:49PM CDT
Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that Jonathan R. Symonds, CBE, the former Chief Financial Officer of Novartis AG, has joined the Company to support the implementation of corporate finance and strategic objectives.
Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020
M2 - Mon Mar 10, 7:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gsw6jj/global_stem_cell) has announced the addition of the "Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020" report to their offering. The market is expected to reach revenue of $56.4 billion by 2020, growing at CAGR of 33.4% during 2013 to 2020 The study observed that the global umbilical cord blood stem cell market is forecasted to reach market value over $11.5 billion in 2014 from $ 6.5 billion in 2012. Developments and approvals for novel cord blood stem cells therapies is expected to drive the market growth. The storage service market was valued at $7.4 billion in 2013. Increase in prevalence rate of chronic diseases such as cancer, diabetes, blood disease, immune disease, metabolic disease etc. has increased the need of cost effective and efficient way of treatment. However, cord blood stem cells have the potential to treat these chronic diseases effectively. These stem cells have special property of higher cell count in lower blood volume. Collection of these stem cells is much easier than other stem cells and could be stored in specialized preservation facilities called as Cord Blood Stem Cell Banks.Cord blood stem cells market is in its emerging phase. Significant applications of stem cells in the treatment of various disorders will be commercialized very soon as most of them are in the last phase of clinical trials. Patents for collection techniques and therapeutics methods are approved by respective government of developed countries however patents for UCB stem cells are comparatively less in developing economies. According to lead analyst Debbie Shields, the geographic analysis shows that the North American market for cord blood stem cell would account for approx. 44% of total revenue generated by the cord blood market in 2013. However, much expected growth is to occur in Asia-Pacific regions during the forecast period, because of growing demand for chronic disease treatments and widely increasing awareness levels. This report study offers updated review about major market players present in this market such as researcher based pharmaceutical companies and therapeutics services companies. Key Market Segments Global Stem cell UCB market by storage - Public cord blood banks - Private cord blood banks - Public Vs. Private UCB banks Global Stem cell UCB market by Diseases - Cancer/ Oncology diseases - Acute Leukemia - Chronic Leukemia - High Risk Solid Tumors - Myelodysplastic Syndrome - Blood diseases - Aplastic Anemia - Beta Thalassemia - Sickle Cell disease - Immune Disorders - Leukocyte Adhesion Deficiency - Hystiocytic Disorders - Wiskott-Aldrich - Metabolic Disorders - Krabbe Disease - Hurler Syndrome - Sanfilippo Syndrome - Other diseases - Osteopetrosis - Hemophagoyticlymphohistiocytosis Global Stem cell UCB market by Technology - Stem Cell Transplant - Autologous transplant - Allogenic transplant - Transplant Medicine - Regenerative Medicine - Others - Cord Blood Banking - Blood Transfusion - Cell Based Genetics Companies Mentioned - Advanced Cell Technology Inc. (USA) - Athersys Inc. - California Stem Cell - Cytori Therapeutics Inc. - Geron Corporation - Mesoblast Limited - NeoStem Inc. - Opexa Therapeutics Inc. - Osiris Therapeutics - Pluristem Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/gs..._stem_cell
Former Roche Pharmaceuticals CEO Joins Mesoblast Board of Directors
GlobeNewswire - Wed Mar 05, 6:24PM CST
Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that William M. Burns, former Chief Executive Officer of Roche Pharmaceuticals, has been appointed a non-executive Director of the Mesoblast Board, effective immediately.
Mesoblast Reports Strong Half-Year Financial Results
GlobeNewswire - Tue Feb 25, 4:01PM CST
Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today provided its 2014 half-year financial results and operational highlights.
Bone Marrow Transplantation - Pipeline Review, H1 2014 Research Report
M2 - Mon Feb 24, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/f8glf8/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H1 2014" report to their offering. 'Bone Marrow Transplantation - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bone Marrow Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation. Scope - A snapshot of the global therapeutic scenario for Bone Marrow Transplantation. - A review of the Bone Marrow Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bone Marrow Transplantation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Bone Marrow Transplantation Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Bone Marrow Transplantation - Therapeutics Assessment Drug Profiles Allogeneic MPC For Bone Marrow Transplantation - Drug Profile melphalan - Drug Profile TM-400 - Drug Profile PLX-BMP - Drug Profile CBLB-612 - Drug Profile CBLB-612 - Drug Profile Perforin Inhibitor - Drug Profile R&D Progress Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Mesoblast Limited Cleveland BioLabs, Inc. Pluristem Therapeutics Inc. Spectrum Pharmaceuticals, Inc. TikoMed AB For more information visit http://www.researchandmarkets.com/research/f8...one_marrow About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
KEY EUROPEAN PATENT GRANTED FOR USE OF MESOBLAST'S MESENCHYMAL PRECURSOR CELLS IN CARDIAC AND VASCULAR CONDITIONS
GlobeNewswire - Wed Feb 19, 8:03PM CST
Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that it has been granted a key patent by the European Patent Office covering its proprietary adult Mesenchymal Precursor Cells (MPCs) for use in the treatment of cardiac and vascular conditions. European patent number EP1613335, entitled 'Perivascular Mesenchymal Precursor Cell Induced Blood Vessel Formation', provides Mesoblast with exclusive commercial rights in Europe initially through to 29 March 2024, with potential for extension based on duration of clinical development.
Cartilage Degeneration - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 17, 3:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/hzb6kb/cartilage) has announced the addition of the "Cartilage Degeneration - Pipeline Review, H2 2013" report to their offering. 'Cartilage Degeneration - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cartilage Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cartilage Degeneration. Scope - A snapshot of the global therapeutic scenario for Cartilage Degeneration. - A review of the Cartilage Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cartilage Degeneration pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Cartilage Degeneration Overview Therapeutics Development Clinical Stage Products Early Stage Products Cartilage Degeneration - Products under Development by Companies Cartilage Degeneration - Companies Involved in Therapeutics Development Cartilage Degeneration - Therapeutics Assessment Drug Profiles sprifermin - Drug Profile Chondrogen - Drug Profile MSB-CAR-001 - Drug Profile AOD-9604 - Drug Profile THR-166 - Drug Profile ST-03 - Drug Profile Cartilage Degeneration - Recent Pipeline Updates Appendix List of Tables List of Figures Companies Mentioned Sanofi Merck KGaA Mesoblast Limited Calzada Limited Thrasos, Inc. For more information visit http://www.researchandmarkets.com/research/hzb6kb/cartilage About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Akpabio - No Apology for Supporting Jonathan [interview]
All Africa Global Media - Thu Feb 13, 4:36AM CST
The Akwa Ibom State Governor, Godswill Akpabio, after paying a courtesy call on the National Chairman of the Peoples Democratic Party, Adamu Mu'azu, pledged his support to the new authority. Chuks Okocha presents excerpts of the session
Boardroom Radio Interview with Mesoblast Chief Executive
GlobeNewswire - Sun Feb 02, 7:07PM CST
Audio link - http://www.brrmedia.com/event/120127
POSITIVE SPINAL DISC REPAIR TRIAL RESULTS USING MESOBLAST ADULT STEM CELLS
GlobeNewswire - Wed Jan 29, 5:31PM CST
Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced positive 12 month outcome results from the 100-patient Phase 2 clinical trial of its proprietary allogeneic, or "off-the-shelf", Mesenchymal Precursor Cells (MPCs) in patients with chronic moderate to severe discogenic low back pain.
Akingbola Challenges Lagos High Court's Jurisdiction
All Africa Global Media - Fri Jan 17, 1:23AM CST
Mr Erastus Akingbola, a former Managing Director of the defunct Intercontinental Bank Plc, on Thursday challenged the jurisdiction of a Lagos High Court to register a judgment against him by a London court.
2013 Report on the International Regenerative Medicine Markets
M2 - Mon Jan 13, 8:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/3gvqj4/regenerative) has announced the addition of the "2013 Report on the International Regenerative Medicine Markets" report to their offering. Astounding new advancements in the ability to repair or replace damaged human tissue and organ functions are being made. Whereas before, remedies for damaged tissue or organ functions due to congenital deformities, injuries, diseases or simple wear-and-tear relied upon either the body's ability to repair itself (or not), or a surgeon's skilled hands. Now, the area of regenerative medicine promises to revolutionize humanity's ability to remediate countless physical maladies that have perpetually afflicted humans and other animals. Compared to a select few life forms--like the starfish--man-made solutions for tissue repair and organ replacement haven't come close to nature's solutions. And where there once was no solution even offered by nature, researchers are now at the cusp of overcoming such limitations by "2013 Report on the International Regenerative Medicine Markets", enables the reader gain in-depth knowledge about ongoing tissue engineering and stem cell therapy research programs carried out in universities and other research centers. Moreover, this analysis profiles the leading companies developing regenerative medicine solutions. Key Topics Covered: 1. Overview 2. Regenerative Medicines: An Overview of Segments 3. Regenerative Medicine: The Next Evolution of Medical Treatment 4. Recent Advances in Regenerative Medicine and Stem Cell Research 5. Stem Cell Industry Highlights 6. Regenerative Medicines: A Brief Update from Selected Countries 7. Market Analysis for Regenerative Medicine Sector 8. Stem Cell Industry 9. Business Models and Requirements for a Successful Regenerative Medicine Industry 10. Company Profiles Companies Mentioned: - Aastrom Biosciences, Inc. - Advanced Cell Technology, Inc. (ACT) - Aldagen, Inc. - BeFutur Biotechnologies - Cardio BioSciences - CardioPolymers, Inc. - Develogen AG - Effector Cell Institute, Inc (ECI) - Epistem plc - FivePrime Therapeutics, Inc. - Forticell Bioscience, Inc. - Geron Corporation - Hydra Biosciences, Inc. - Intercytex Group plc - Japan Tissue Engineering, Co., Ltd. - Karocell Tissue Engineering AB - LifeCell - MaxCyte, Inc. - Mesoblast Ltd. - NanoCor's Products - Olympus Terumo Biomaterials Corporation - Pervasis Therapeutics, Inc. - RegeneRx - SyntheMed, Inc. - Thermogenesis Corp. - t cure GmbH For more information visit http://www.researchandmarkets.com/research/3g...generative
Diabetic Nephropathy - Pipeline Review, H1 2014: 37 Companies and 58 Drugs Profiled
M2 - 31 mins ago
Research and Markets (http://www.researchandmarkets.com/research/x6n63h/diabetic) has announced the addition of the "Diabetic Nephropathy - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Nephropathy and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diabetic Nephropathy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diabetic Nephropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved: - AbbVie Inc. - Ampio Pharmaceuticals, Inc. - Angelini Group - Astellas Pharma Inc. - Bayer AG - CCRP Therapeutics GmbH - ChemoCentryx, Inc. - Chong Kun Dang Pharmaceutical Corp. - Concert Pharmaceuticals, Inc. - Cyano Biotech GmbH - Daiichi Sankyo Company, Limited - Dongwha Pharm Co., Ltd. - Eli Lilly and Company - Emergent BioSolutions Inc. - Fibrotech Therapeutics Pty. Ltd. - GNI Group Ltd. - Galectin Therapeutics - GenKyoTex S.A. - Gentium S.p.A. - Glucox Biotech AB - IMMD Inc. - Intercept Pharmaceuticals, Inc. - Inventiva SAS - Johnson & Johnson - Mesoblast Limited - Mitsubishi Pharmaceutical Corporation - Mitsubishi Tanabe Pharma Corporation - NephroGenex, Inc. - Noxxon Pharma AG Drug Profiles: - canagliflozin - atrasentan hydrochloride - baricitinib - NOX-E-36 - IMD-1041 - CS-3150 - DW-1029M - GKT-137831 - PF-00489791 - CCX-140 - LY-2382770 - bindarit - Colchicine - probucol - PF-04634817 - Pyridoxamine Dihydrochloride - GLY-230 - corticotropin - CTP-499 - MT-3995 - finerenone - cilostazol - PHN-033 - CKD-322 - Allogeneic Mesenchymal Precursor Cells For Diabetic Nephropathy - LY-3016859 - FT-011 - ASP-8232 - pirfenidone - THR-123 For more information visit http://www.researchandmarkets.com/research/x6n63h/diabetic
Angina (Angina Pectoris) - Pipeline Review, H1 2014: 11 Company and 15 Drug Profiles
M2 - Wed May 07, 9:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/shfvfz/angina_angina) has announced the addition of the "Angina (Angina Pectoris) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Angina (Angina Pectoris), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Angina (Angina Pectoris) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - Bayer AG - Cardiolynx AG - Cardium Therapeutics, Inc. - Cheiljedang Corporation - Diakron Pharmaceuticals, Inc. - Juventas Therapeutics, Inc. - Kuhnil Pharmaceutical Co., Ltd. - Lacer, S.A. - Mesoblast Limited - Milestone Pharmaceuticals, Inc. - ViroMed Co., Ltd. Drug Profiles: - alferminogene tadenovec - VM-202 - VM-202 - CJ-30059 - ACP-01 - Organic Nitrate For Angina Pectoris - CLC-1201 - DP-3005 - JVS-100 - CEP-41750 - LA-8045 - MSP-2017 - BAY-606583 - KI-1007 - R-06 For more information visit http://www.researchandmarkets.com/research/sh...ina_angina
Chronic Heart Failure - Pipeline Review, H1 2014: 22 Company and 30 Drugs Profiled
M2 - Wed May 07, 9:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dlbpvz/chronic_heart) has announced the addition of the "Chronic Heart Failure - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Heart Failure and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - Bayer AG - Cardioxyl Pharmaceuticals, Inc. - Celladon Corporation - Cyano Biotech GmbH - Fibrotech Therapeutics Pty. Ltd. - Hospira, Inc. - Laboratoires Pierre Fabre SA - Les Laboratoires Servier SAS - Mesoblast Limited - MetrioPharm AG - NormOxys, Inc. - Novartis AG - Otsuka Holdings Co., Ltd. - Palatin Technologies, Inc. - Pfizer Inc. - PhaseBio Pharmaceuticals, Inc. - Provasculon, Inc. - Sanofi - Scynexis, Inc. - Zensun (Shanghai) Sci & Tech Co., Ltd. - miRagen Therapeutics, Inc. - t2cure GmbH Drug Profiles: - Neucardin - rivaroxaban - (AHU-377 valsartan) - CEP-41750 - aliskiren fumarate - sildenafil citrate - PL-3994 - CXL-1020 - tolvaptan - somatropin - Neucardin - finerenone - ivabradine - F-373280 - BMCs - cenderitide - OXY-111A - MGN-9103 - MP-2000 - BR-5489 - Small Molecule Allosteric Modulators Of SERCA2a - FT-011 - PB-1046 - SAR-296968 - PRV-0023 - Cyclophilin Inhibitory Compounds - etomoxir - PRV-0023 - Microginins ACE Inhibitors? Program - Vestiras For more information visit http://www.researchandmarkets.com/research/dl...onic_heart
Stem Cell Therapy Market by Treatment Mode (Autologous & Allogeneic), Therapeutic Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) - Global Forecasts to 2020
M2 - Tue May 06, 10:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wwnrd5/stem_cell_therapy) has announced the addition of the "Stem Cell Therapy Market by Treatment Mode (Autologous & Allogeneic), Therapeutic Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) - Regulatory Landscape, Pipeline Analysis & Global Forecasts to 2020" report to their offering. The global stem cell therapy market on the basis of the mode of treatment is segmented into allogeneic and autologous stem cell therapy. The allogeneic stem cell therapy is expected to command the largest share of the market in 2015, and is also expected to grow at a higher CAGR than autologous therapies from 2015 to 2020. Based on the therapeutic applications, the global market is segmented into eye diseases, metabolic diseases, GIT diseases, musculoskeletal disorders, immune system diseases, CNS diseases, CVS diseases, wounds and injuries, and others. A number of factors such as increasing funding from government and private organizations, growing industry focus on stem cell research, and increasing global awareness about stem cell therapies through various organizations are driving the growth of the global market. Furthermore, increasing funding for new stem cell lines, development of advanced genomic methods for stem cell analysis, and rising approvals of clinical trials for stem cells therapy are other factors that are propelling the growth of the market. Key Topics Covered: 1 INTRODUCTION 2 EXECUTIVE SUMMARY 3 MARKET DYNAMICS 4 PIPELINE ANALYSIS 5 INVESTOR NETWORK 6 GLOBAL STEM CELL THERAPY MARKET, BY MODE OF THERAPY 7 GLOBAL STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATIONS 8 REGULATORY LANDSCAPE 9 GLOBAL STEM CELL THERAPY MARKET, BY GEOGRAPHY 10 COMPETITIVE LANDSCAPE 11 COMPANY PROFILES Companies Mentioned: - Aastrom Biosciences Inc. - Advanced Cell Technologies, Inc. - Athersys Inc. - Celgene Corporation - Cellular Dynamics International - Cytori Therapeutics, Inc. - Fibrocell Science, Inc. - Gamida Cell Ltd. - Mesoblast Ltd. - Pluristem Therapeutics Inc. - StemCells Inc. For more information visit http://www.researchandmarkets.com/research/ww...ll_therapy
Mesoblast Provides Update on Clinical Programs of Prochymal for Crohn's Disease and Acute Graft Versus Host Disease
GlobeNewswire - Mon Apr 28, 8:54PM CDT
Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today provided an update on its clinical programs using the product Prochymal(R), which was acquired as part of the entire culture-expanded mesenchymal stem cell (MSC) business of Osiris Therapeutics (NASDAQ:OSIR) by the Mesoblast Group.
Global Bone Marrow Transplantation Therapeutic Pipeline Review
M2 - Mon Apr 28, 11:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lrc2d3/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Marrow Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation and special features on late-stage and discontinued projects. Companies Involved in Therapeutics Development - Mesoblast Limited - Cleveland BioLabs, Inc. - Compugen Ltd. - Pluristem Therapeutics Inc. - Spectrum Pharmaceuticals, Inc. - TikoMed AB - Taiga Biotechnologies, Inc. Drug Profiles - Allogeneic MPC For Bone Marrow Transplantation - melphalan - TM-400 - PLX-BMP - CBLB-612 - CBLB-612 - CGEN-15001 - Small Molecule to Inhibit Perforin for Bone Marrow Transplantation - Protein for Bone Marrow Transplantation Companies Mentioned: - Mesoblast Limited - Cleveland BioLabs, Inc. - Compugen Ltd. - Pluristem Therapeutics Inc. - Spectrum Pharmaceuticals, Inc. - TikoMed AB - Taiga Biotechnologies, Inc. For more information visit http://www.researchandmarkets.com/research/lr...one_marrow
Osiris receives USD15m cash payment for Prochymal business acquisition
M2 - Thu Apr 10, 7:06AM CDT
US-based stem cell company Osiris Therapeutics (NasdaqGM :OSIR) reported on Wednesday the receipt of the next payment of USD15m in cash from Mesoblast under the Purchase Agreement relating to the Prochymal business.
Osiris Announces Receipt of $15 Million Cash Payment for Prochymal
Business Wire - Wed Apr 09, 7:01AM CDT
Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading stem cell company focused on developing and marketing products to treat conditions in wound care, orthopedic and sports medicine markets, announced that it has received the next $15 million cash payment from Mesoblast in accordance with the Purchase Agreement relating to the Prochymal business.
Key Pharmaceutical Executive Joins Mesoblast
GlobeNewswire - Mon Mar 10, 6:49PM CDT
Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that Jonathan R. Symonds, CBE, the former Chief Financial Officer of Novartis AG, has joined the Company to support the implementation of corporate finance and strategic objectives.
Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020
M2 - Mon Mar 10, 7:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gsw6jj/global_stem_cell) has announced the addition of the "Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020" report to their offering. The market is expected to reach revenue of $56.4 billion by 2020, growing at CAGR of 33.4% during 2013 to 2020 The study observed that the global umbilical cord blood stem cell market is forecasted to reach market value over $11.5 billion in 2014 from $ 6.5 billion in 2012. Developments and approvals for novel cord blood stem cells therapies is expected to drive the market growth. The storage service market was valued at $7.4 billion in 2013. Increase in prevalence rate of chronic diseases such as cancer, diabetes, blood disease, immune disease, metabolic disease etc. has increased the need of cost effective and efficient way of treatment. However, cord blood stem cells have the potential to treat these chronic diseases effectively. These stem cells have special property of higher cell count in lower blood volume. Collection of these stem cells is much easier than other stem cells and could be stored in specialized preservation facilities called as Cord Blood Stem Cell Banks.Cord blood stem cells market is in its emerging phase. Significant applications of stem cells in the treatment of various disorders will be commercialized very soon as most of them are in the last phase of clinical trials. Patents for collection techniques and therapeutics methods are approved by respective government of developed countries however patents for UCB stem cells are comparatively less in developing economies. According to lead analyst Debbie Shields, the geographic analysis shows that the North American market for cord blood stem cell would account for approx. 44% of total revenue generated by the cord blood market in 2013. However, much expected growth is to occur in Asia-Pacific regions during the forecast period, because of growing demand for chronic disease treatments and widely increasing awareness levels. This report study offers updated review about major market players present in this market such as researcher based pharmaceutical companies and therapeutics services companies. Key Market Segments Global Stem cell UCB market by storage - Public cord blood banks - Private cord blood banks - Public Vs. Private UCB banks Global Stem cell UCB market by Diseases - Cancer/ Oncology diseases - Acute Leukemia - Chronic Leukemia - High Risk Solid Tumors - Myelodysplastic Syndrome - Blood diseases - Aplastic Anemia - Beta Thalassemia - Sickle Cell disease - Immune Disorders - Leukocyte Adhesion Deficiency - Hystiocytic Disorders - Wiskott-Aldrich - Metabolic Disorders - Krabbe Disease - Hurler Syndrome - Sanfilippo Syndrome - Other diseases - Osteopetrosis - Hemophagoyticlymphohistiocytosis Global Stem cell UCB market by Technology - Stem Cell Transplant - Autologous transplant - Allogenic transplant - Transplant Medicine - Regenerative Medicine - Others - Cord Blood Banking - Blood Transfusion - Cell Based Genetics Companies Mentioned - Advanced Cell Technology Inc. (USA) - Athersys Inc. - California Stem Cell - Cytori Therapeutics Inc. - Geron Corporation - Mesoblast Limited - NeoStem Inc. - Opexa Therapeutics Inc. - Osiris Therapeutics - Pluristem Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/gs..._stem_cell
Former Roche Pharmaceuticals CEO Joins Mesoblast Board of Directors
GlobeNewswire - Wed Mar 05, 6:24PM CST
Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that William M. Burns, former Chief Executive Officer of Roche Pharmaceuticals, has been appointed a non-executive Director of the Mesoblast Board, effective immediately.
Mesoblast Reports Strong Half-Year Financial Results
GlobeNewswire - Tue Feb 25, 4:01PM CST
Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today provided its 2014 half-year financial results and operational highlights.
Bone Marrow Transplantation - Pipeline Review, H1 2014 Research Report
M2 - Mon Feb 24, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/f8glf8/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H1 2014" report to their offering. 'Bone Marrow Transplantation - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bone Marrow Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation. Scope - A snapshot of the global therapeutic scenario for Bone Marrow Transplantation. - A review of the Bone Marrow Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bone Marrow Transplantation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Bone Marrow Transplantation Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Bone Marrow Transplantation - Therapeutics Assessment Drug Profiles Allogeneic MPC For Bone Marrow Transplantation - Drug Profile melphalan - Drug Profile TM-400 - Drug Profile PLX-BMP - Drug Profile CBLB-612 - Drug Profile CBLB-612 - Drug Profile Perforin Inhibitor - Drug Profile R&D Progress Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Mesoblast Limited Cleveland BioLabs, Inc. Pluristem Therapeutics Inc. Spectrum Pharmaceuticals, Inc. TikoMed AB For more information visit http://www.researchandmarkets.com/research/f8...one_marrow About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
KEY EUROPEAN PATENT GRANTED FOR USE OF MESOBLAST'S MESENCHYMAL PRECURSOR CELLS IN CARDIAC AND VASCULAR CONDITIONS
GlobeNewswire - Wed Feb 19, 8:03PM CST
Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that it has been granted a key patent by the European Patent Office covering its proprietary adult Mesenchymal Precursor Cells (MPCs) for use in the treatment of cardiac and vascular conditions. European patent number EP1613335, entitled 'Perivascular Mesenchymal Precursor Cell Induced Blood Vessel Formation', provides Mesoblast with exclusive commercial rights in Europe initially through to 29 March 2024, with potential for extension based on duration of clinical development.
Cartilage Degeneration - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 17, 3:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/hzb6kb/cartilage) has announced the addition of the "Cartilage Degeneration - Pipeline Review, H2 2013" report to their offering. 'Cartilage Degeneration - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cartilage Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cartilage Degeneration. Scope - A snapshot of the global therapeutic scenario for Cartilage Degeneration. - A review of the Cartilage Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cartilage Degeneration pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Cartilage Degeneration Overview Therapeutics Development Clinical Stage Products Early Stage Products Cartilage Degeneration - Products under Development by Companies Cartilage Degeneration - Companies Involved in Therapeutics Development Cartilage Degeneration - Therapeutics Assessment Drug Profiles sprifermin - Drug Profile Chondrogen - Drug Profile MSB-CAR-001 - Drug Profile AOD-9604 - Drug Profile THR-166 - Drug Profile ST-03 - Drug Profile Cartilage Degeneration - Recent Pipeline Updates Appendix List of Tables List of Figures Companies Mentioned Sanofi Merck KGaA Mesoblast Limited Calzada Limited Thrasos, Inc. For more information visit http://www.researchandmarkets.com/research/hzb6kb/cartilage About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Akpabio - No Apology for Supporting Jonathan [interview]
All Africa Global Media - Thu Feb 13, 4:36AM CST
The Akwa Ibom State Governor, Godswill Akpabio, after paying a courtesy call on the National Chairman of the Peoples Democratic Party, Adamu Mu'azu, pledged his support to the new authority. Chuks Okocha presents excerpts of the session
Boardroom Radio Interview with Mesoblast Chief Executive
GlobeNewswire - Sun Feb 02, 7:07PM CST
Audio link - http://www.brrmedia.com/event/120127
POSITIVE SPINAL DISC REPAIR TRIAL RESULTS USING MESOBLAST ADULT STEM CELLS
GlobeNewswire - Wed Jan 29, 5:31PM CST
Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced positive 12 month outcome results from the 100-patient Phase 2 clinical trial of its proprietary allogeneic, or "off-the-shelf", Mesenchymal Precursor Cells (MPCs) in patients with chronic moderate to severe discogenic low back pain.
Akingbola Challenges Lagos High Court's Jurisdiction
All Africa Global Media - Fri Jan 17, 1:23AM CST
Mr Erastus Akingbola, a former Managing Director of the defunct Intercontinental Bank Plc, on Thursday challenged the jurisdiction of a Lagos High Court to register a judgment against him by a London court.
2013 Report on the International Regenerative Medicine Markets
M2 - Mon Jan 13, 8:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/3gvqj4/regenerative) has announced the addition of the "2013 Report on the International Regenerative Medicine Markets" report to their offering. Astounding new advancements in the ability to repair or replace damaged human tissue and organ functions are being made. Whereas before, remedies for damaged tissue or organ functions due to congenital deformities, injuries, diseases or simple wear-and-tear relied upon either the body's ability to repair itself (or not), or a surgeon's skilled hands. Now, the area of regenerative medicine promises to revolutionize humanity's ability to remediate countless physical maladies that have perpetually afflicted humans and other animals. Compared to a select few life forms--like the starfish--man-made solutions for tissue repair and organ replacement haven't come close to nature's solutions. And where there once was no solution even offered by nature, researchers are now at the cusp of overcoming such limitations by "2013 Report on the International Regenerative Medicine Markets", enables the reader gain in-depth knowledge about ongoing tissue engineering and stem cell therapy research programs carried out in universities and other research centers. Moreover, this analysis profiles the leading companies developing regenerative medicine solutions. Key Topics Covered: 1. Overview 2. Regenerative Medicines: An Overview of Segments 3. Regenerative Medicine: The Next Evolution of Medical Treatment 4. Recent Advances in Regenerative Medicine and Stem Cell Research 5. Stem Cell Industry Highlights 6. Regenerative Medicines: A Brief Update from Selected Countries 7. Market Analysis for Regenerative Medicine Sector 8. Stem Cell Industry 9. Business Models and Requirements for a Successful Regenerative Medicine Industry 10. Company Profiles Companies Mentioned: - Aastrom Biosciences, Inc. - Advanced Cell Technology, Inc. (ACT) - Aldagen, Inc. - BeFutur Biotechnologies - Cardio BioSciences - CardioPolymers, Inc. - Develogen AG - Effector Cell Institute, Inc (ECI) - Epistem plc - FivePrime Therapeutics, Inc. - Forticell Bioscience, Inc. - Geron Corporation - Hydra Biosciences, Inc. - Intercytex Group plc - Japan Tissue Engineering, Co., Ltd. - Karocell Tissue Engineering AB - LifeCell - MaxCyte, Inc. - Mesoblast Ltd. - NanoCor's Products - Olympus Terumo Biomaterials Corporation - Pervasis Therapeutics, Inc. - RegeneRx - SyntheMed, Inc. - Thermogenesis Corp. - t cure GmbH For more information visit http://www.researchandmarkets.com/research/3g...generative
